Overview

N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome

Status:
Withdrawn

Trial end date:
2021-01-30

Target enrollment:
0

Participant gender:
All

Summary

We would study whether there is any measurable benefit of the administration of nebulized n-acetyl-cysteine to acute respiratory distress syndrome patients starting within 48 hours of intubation and mechanical ventilation.

Phase:

Early Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Palmetto Health
Prisma Health-Midlands

Treatments:

Acetylcysteine
Albuterol
N-monoacetylcystine

Criteria

Inclusion Criteria:

- Inclusion criteria includes adult patients admitted to the medical intensive care unit
or coronary care unit, being mechanically ventilated with a positive end expiratory
pressure greater than 5 cm H2O, with noncardiogenic pulmonary edema on chest x-ray
within 48 hours of being noted to have a P/F ratio < 150.

Exclusion Criteria:

- Exclusion criteria includes patients < 18 years of age, patients for whom no
aggressive measures are desired, patients who are already receiving "rescue methods"
(prone positioning, advanced ventilator modes, paralytics), trauma patients,
vulnerable patient groups (pregnant, prisoners), patients who have undergone a
surgical operation during their time on the ventilator, patients with end stage liver
disease, patients on chronic ventilators, and asthmatics.